Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 60%Moderate 0 · 0%High 1 · 20%

Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with different dose of the same anticoagulant (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.47 [0.09, 2.54]
1 study · 278 participants
Low

Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with antiplatelet agent (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 2.13 [0.4, 11.46]
1 study · 279 participants
Low

Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with placebo or no treatment (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 2.46 [0.9, 6.72]
5 studies · 1777 participants
Low

Adverse events (minor bleeding) · people hospitalised with COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulants for people hospitalised with COVID‐19: a rapid review 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Adverse events (minor bleeding) · people hospitalised with COVID‐19

Higher‐dose anticoagulants leads to higher adverse events (minor bleeding) compared with lower‐dose anticoagulants (high certainty).

1 finding from 1 review

Anticoagulants for people hospitalised with COVID‐19: a rapid review 2022 · Cochrane Headline outcomes only
RR 3.28 [1.75, 6.14]
3 studies · 1196 participants
High